Cabaletta Bio’s RESET Trial Shows Promising Results in Autoimmune Disease Treatment, Supporting Buy Rating
William Blair analyst Sami Corwin has maintained their bullish stance on CABA stock, giving a Buy rating on November 15.Don't Miss our Black ...